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Abstract 
Antimicrobial photodynamic therapy (PDT) has lately attracted much attention among 
clinicians for the treatment of pathogenic biofilm associated with peridontitis and peri-
implantitis. However, at present, the data from randomized controlled clinical studies 
(RCTs) are still limited and, to some extent, controversial which makes it difficult to 
provide appropriate recommendations for the clinician.   
Therefore, the aims of the present study were: a) to provide an overview on the 
current evidence from randomized controlled clinical studies evaluating the potential 
clinical benefit for the additional use of PDT to subgingival mechanical debridement 
(i.e. scaling and root planing (SRP)) alone in nonsurgical periodontal therapy and b) 
to provide clinical recommendations for the use of PDT in periodontal practice.  
Based on the available evidence from RCTs the following conclusions can be drawn:  
- In patients with chronic periodontitis (ChP) the combination of SRP and PDT 
may result in substantially higher short-term clinical improvements evidenced 
by probing depth (PD) and/or bleeding on probing (BOP) reductions compared 
to SRP alone. 
- In patients with aggressive periodontitis (AgP) the use of PDT cannot replace 
the systemic administration of amoxicillin and metronidazole. Due to lack of 
data, no conclusions can be made to what extent PDT may replace the use of 
systemic antibiotics in patients with ChP. 
- Limited evidence from one study indicates that PDT may represent a possible 
alternative to local antibiotics in patients with incipient peri-implantitis.    
 
Key Words:  Photodynamic therapy, chronic periodontitis, aggressive 
periodontitis, peri-implantitis, antibiotics, bacterial biofilm  
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Biological rationale 
Periodontitis is a multifactorial disease which is associated with loss of the supporting 
tissues (i.e. periodontal ligament and alveolar bone) around the tooth.1 A major 
objective of periodontal therapy is to remove soft and hard, supra- and subgingival 
deposits from the root surface in order to stop disease progression.2 Numerous 
studies have reported significant improvements of clinical and microbial parameters 
following nonsurgical periodontal therapy.3-6  
Despite the fact that non-surgical periodontal treatment may result in significant 
clinical improvements in the great majority of cases, evidence indicates that none of 
the currently available instrumentation techniques are effective in completely 
eliminating subgingival bacterial biofilm.7 These limitations may be attributed to 
several factors such as the complex anatomy of teeth (i.e. furcation involvements, 
root invaginations), presence of intrabony defects, etc., mechanical limitations related 
to the size of instruments or invasion of periodontal pathogens into the surrounding 
soft tissues or possible recolonization of periodontal pockets from other diseased 
sites or intraoral niches.8 Power-driven instruments (i.e. sonic and ultrasonic scalers) 
have been introduced to further enhance the effectiveness of scaling and root planing 
(SRP). However, findings from clinical studies have also shown comparative 
outcomes following power-driven and manual instrumentation.9 
Thus, the current evidence indicates that nonsurgical periodontal treatment may 
result in substantial clinical improvements in the great majority of cases, but none of 
the currently available instrumentation techniques are able to completely eliminate 
subgingival bacteria and calculus.7  
Photodynamic therapy (PDT), also called photoradiation therapy, phototherapy, 
photochemotherapy, photo-acrivated disinfection (PAD), or light-activated disinfection 
(LAD), was introduced in medical therapy in 1904 as the light-induced inactivation of 
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cells, microorganisms or molecules and involves the combination of visible light, 
usually through the use of a diode laser and a photosensitizer.10  
The photosensitizer is a substance that is capable to absorb light of a specific 
wavelength and transform it into useful energy. Each factor is harmless by itself, but 
when combined they can produce lethal cytotoxic agents that can selectively destroy 
cells.11 
Thus, PDT has been proposed as a modality to reduce bacterial load or even to 
eliminate periodontal pathogens.12, 13 The action mechanism of PDT has been 
extensively described previously.14 Briefly, upon illumination the photosensitizer is 
excited from the ground state to the triplet state. The longer lifetime of the triplet state 
enables the interaction of the excited photosensitizer with the surrounding molecules. 
It is anticipated that the generation of the cytotoxic species produced during PDT 
occurs while in this state.15, 16 The cytotoxic product, usually singlet oxygen (1O2), 
cannot migrate at a distance more than 0.02 μm after its formation, thus making it 
ideal for local application of PDT, without endangering distant molecules, cells or 
organs.16 
In vitro studies have revealed that light from a Helium/Neon (HE/Ne) laser or a 
Gallium-Aluminum-Arsenide (GaAlAs) laser, in combination with appropriate 
photosensitizers, can achieve a significant reduction in the viability of both aerobic 
and anaerobic bacteria in a solution of subgingival plaque from patients with chronic 
periodontitis.17, 18 Dobson & Wilson (1992) have shown that bacteria associated with 
periodontal disease can be killed through photosensitization with Toluidine Blue – O 
(TBO) and irradiation with a He/Ne soft laser.19 Subsequent studies in animals have 
shown PDT was distinctly advantageous in reducing the periodontal signs of redness 
and bleeding on probing, and significantly suppressed P. gingivalis.20  
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During the last decade, a considerable interest has evolved in evaluating the use of 
PDT in the treatment of periodontal and peri-implant infections. However, despite the 
relatively abundant literature, the data on the clinical relevance of PDT when used in 
conjunction with mechanical therapy are still controversial and difficult to interpret for 
the clinician. 
Therefore, the aims of this review article are: a) to provide an overview of the current 
evidence from randomized controlled clinical studies (RCTs) evaluating the potential 
clinical benefit for the additional use of PDT to mechanical debridement alone in 
nonsurgical periodontal therapy and b) to provide clinical recommendations for the 
use of PDT in periodontal practice.   
 
 
Use of PDT as adjunct to nonsurgical periodontal therapy in patients with 
untreated chronic periodontitis (ChP) 
A total of 18 RCTs have compared the potential additional benefit of PDT to SRP 
with the use of SRP alone in untreated periodontitis patients (Table 1). Eight out of 
the 18 studies have reported statistically significantly higher improvements in probing 
depth (PD) reduction and/or clinical attachment (CAL) gain following SRP + PDT 
compared to SRP alone,21-28 _ENREF_22while the rest of 10 studies have failed to 
reveal statistically significant differences in these parameters.29,30-38 An additional 
improvement for the reduction of bleeding on probing (BOP) following the use of PDT 
was reported in 5 out of the 19 papers.22, 26, 28, 31, 32 Changes of microbiological 
parameters were evaluated in 8 of 18 studies. Four studies have found a statistically 
significant effect of the additional use of PDT on the reduction of periodontal 
pathogens, 28, 35, 37, 38 while 4 studies have failed to reveal any differences between 
the treatments groups.31, 33, 36, 39 Three out of the 18 studies have also evaluated the 
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changes in terms of various inflammatory markers.29, 33, 34 All three studies have 
revealed statistically significantly higher reductions in the investigated inflammatory 
markers following the additional use of PDT (Table 1).   
 
Use of PDT as adjunct to nonsurgical periodontal therapy in patients with 
Aggressive Periodontitis (AgP) 
 
Two RCTs have compared treatment with SRP + PDT to treatment with SRP 
alone,40, 41 and another study has compared SRP alone to PDT alone (i.e. without 
any mechanical debridement).42, 43 (Table 2). While one study has found in deep 
pockets (PD ≥ 7 mm) statistically significant improvements in terms of PD reduction 
and CAL gain and significantly less periodontal pathogens of the red and orange 
complex and IL-1β/IL-10 ratio following treatment with PDT,41 the other study has 
failed to reveal any statistical significant differences in the evaluated clinical and 
microbiological parameters between the treatments40 (Table 2).  
 
 
Use of PDT as adjunct to nonsurgical periodontal therapy in maintenance 
periodontitis patients  
Eight RCTs have evaluated the potential additional benefit of PDT to SRP as 
compared with the use of SRP alone in maintenance patients (Table 3). Two out of 
the 8 studies have reported statistically significantly higher improvements in PD 
reduction and CAL gain following SRP + PDT compared to SRP alone.44, 45 An 
additional improvement for the reduction of BOP was reported in 5 out of the 8 
studies.44-48  
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While three studies have found a statistically significant effect of the additional use of 
PDT on the reduction of periodontal pathogens,46-48 three other studies have failed to 
reveal statistically significant differences between the treatment groups.49-51 Three 
out of the 8 studies have also evaluated the changes in terms of inflammatory 
markers.47, 50, 52 Two studies have revealed statistically significantly higher reductions 
in the investigated inflammatory markers following the use of PDT,47, 50 while one 
study detected no differences 52 (Table 3).   
 
Use of PDT as an alternative to systemic or local antibiotics  
An extremely important aspect which needs to be kept in mind when considering the 
use of PDT, is the lack of bacterial resistance which gains even more importance in 
the light of the worldwide increase in bacterial resistance against antibiotics.53 Thus, 
its repeated application in conjunction with mechanical debridement may represent a 
valuable future option for treating periodontal and peri-implant infections.11, 54 At 
present, there is however limited evidence on the possibility of PDT to replace 
systemic or local antibiotics.  
A recent RCT study has evaluated the treatment of patients with AgP by means of 
nonsurgical periodontal therapy in conjunction with either systemic administration of 
amoxicillin and metronidazole or two-times topical application of PDT.55, 56 The 
results have shown that both treatment protocols resulted in statistically significant 
improvements in PD reduction, gain of CAL and improvement in BOP compared to 
baseline. The systemic use of amoxicillin and metronidazole yielded however, at both 
3 and 6 months, statistically significantly higher reductions in mean PD compared 
with the treatment using PDT.55, 56 The most important clinical finding was the change 
in the total number of pockets ≥ 7 mm following both treatment protocols. In the PDT 
group, the total number of pockets ≥ 7 mm was reduced from 137 to 45 with the 
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corresponding values of 141 and 3 in the amoxicillin and metronidazole group. 
Moreover, compared to the results at 3 months, at 6 months, an additional decrease 
in the number of pockets ≥ 7 mm was measured.55, 56 On the other hand, the use of 
PDT has also led to statistically and clinically significant improvements compared to 
baseline, although the number of residual pockets needing further therapy was 
substantially higher compared with the use of systemic antibiotics (e.g. 45 vs. 3). The 
changes in clinical parameters were also accompanied by changes in the 
concentration of matrix metalloproteinases 8 and 9 (MMP-8 and -9) in the gingival 
crevicular fluid (GCF).57 However, while in the antibiotic group, a statistically 
significant decrease of MMP-8 GCF level at both 3 and 6 months post treatment was 
observed, these changes were not significant in the PDT group.57 Taken together, 
the available data suggest a rather limited clinical benefit of using PDT in the 
treatment of patients with AgP.40, 42, 43 56, 57 Thus, at the time being, PDT cannot be 
recommended as a replacement for systemic antibiotics in patients with AgP. On the 
other hand, no studies have compared the use of PDT or systemic antibiotics in 
conjunction with nonsurgical treatment in patients with ChP. Therefore, at present no 
conclusions can be made regarding this aspect. 
The use of PDT as a potential alternative to local antibiotics has been recently 
evaluated in a RCT study comparing nonsurgical treatment of incipient peri-
implantitis (sites with PD 4-6 mm, BOP positive and radiographic bone loss ≥2 mm) 
by means of mechanical debridement followed by either use of local antibiotics (e.g. 
minocycline) or application of PDT. The results at six months and at one year have 
failed to reveal statistically or clinically significant differences between the two 
treatment protocols, thus suggesting that PDT may represent a valuable alternative 
to local antibiotics during nonsurgical treatment of incipient peri-implantitis.58, 59  
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Conclusions  
Based on the available evidence from RCTs the following conclusions can be drawn:  
- In patients with ChP the combination of SRP and PDT may result in 
substantially higher short-term clinical improvements evidenced by probing 
depth (PD) and/or bleeding on probing (BOP) reductions compared to SRP 
alone. 
- In patients with aggressive periodontitis (AgP) the use of PDT cannot replace 
the systemic administration of amoxicillin and metronidazole. Due to lack of 
data, no conclusions can be made to what extent PDT may replace the use of 
systemic antibiotics in patients with ChP. 
- Limited evidence from one study indicates that PDT may represent a possible 
alternative to local antibiotics in patients with incipient peri-implantitis.    
 
Clinical recommendations 
1. In patients with ChP, clinicians may consider the use of PDT in conjunction 
with subgingival mechanical debridement. However, due to limitations in 
time and costs, the use of PDT appears to be more suitable in the 
maintenance phase of therapy. 
2. At present, the use of PDT cannot be recommended as an alternative to 
systemic antibiotics in the treatment of AgP or severe cases of ChP.  
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Figures 1 and 2: Clinical applications of PDT 
 
Figure 1. Application of the phenothiazine chloride dye following subgingival SRP 
 
 
 
 
Figure 2. Application of the low level laser light into the pocket  
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Tables 1, 2 and 3: Randomized clinical controlled studies, with SRP as control group 
 
 
Table 1. Photodynamic therapy as initial periodontal therapy in patients with ChP (data of 18 studies reported in 19 publications) 
 
Study  
Author 
Year 
Country 
Type 
Diagnosis Patients 
Female/male 
Age 
Smokers 
Study 
duration 
Treatment Photosensitizer 
Laser 
Laser 
parameters 
Microbiology 
 
Immunology PD reduction (mm) 
CAL gain (mm) 
BOP reduction (%) 
Al-Zahrani & 
Austah (2011)21 
Saudi-Arabia 
Split-mouth, RCT 
ChP n=17  
0/17 
41.6 ± 9.6 
17 smokers 
3 
months 
Test: 
SRP + PDT 
(1x) 
Control: 
SRP 
Methylene blue 
(Ondine`s 
Periowave, 
Ondine 
Biopharma, 
Vancouver, BC) 
Diode laser 
Wavelength 
670 nm 
Not analysed  Not analysed Test: 
PD: from 5.60±0.83 to 
3.84±0.85 * 
CAL: from 6.30±1.44 to 
4.70±1.27 * 
BOP: from 74.50±21.50  
to 41.90±22.30 (n.s.) 
Control: 
PD: from 5.35±0.46 
3.90±0.75 
CAL: from 6.18±1.44 to 
4.80±1.45 
BOP: from 68.00±23.00  
to 45.60 to 19.50. 
Alwaeli et al. 
(2015)22 
Jordan 
Split-mouth, RCT 
ChP N=16 
11/5 
40.9±13.34 
12 
months 
Test: 
SRP+PDT 
Control: 
SRP 
Phenothiazine 
chloride  
Diode Lases 
(HELBO, 
Photodynamic 
Systems, 
Grieskirchen, 
Austria) 
Wavelength 
660 nm, 
Output power 
100mW 
Application 
time: 10s/site, 
6 sites/tooth 
Not analysed Not analysed Test: 
PD: 1.51±1.54* 
CAL: 1.48±1.89* 
BOP: 25%* 
Control: 
PD: 0.66±1.66 
CAL: 0.13±1.7 
BOP: 54% 
Andersen et al. 
(2007)23 
England 
Parallel, RCT 
ChP N=33 
22/11 
53 (18-75) 
unclear 
12 
weeks 
Test 1: PDT 
Test 2: 
SRP+ PDT 
Control: SRP 
Methylene blue 
(Periowave) 
Diode laser 
(Periowave) 
Wavelength 
670 nm 
Energy density 
10-20 J/cm2 
Max. power 
150 mW 
Application 
time 60s/site 
Not analysed Not analysed Test 1: 
PD: 0.67±0.44 (n.r.) 
CAL: 0.14±0.65 (n.r.) 
BOP: 73% (n.r.) 
Test 2: 
PD: 1.11±0.53* 
CAL: 0.86±0.61* 
BOP: 59% (n.s.) 
Control: 
PD: 0.74±0.43 
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CAL: 0.36±0.35 
BOP: 56% 
Balata et al. 
(2013)30 
Brazil 
Split-mouth, RCT 
ChP N=22 
43.18 (31-62) 
 
6 
months 
Test: SRP 
(ultrasonic)+P
DT 
Control: 
SRP 
(ultrasonic) 
Methylene blue 
0.005% 
Low power laser 
(AsGaAl, Photon 
LaseIII, Sao 
Paolo, Brazil) 
Wavelength 
660nm 
Output power 
100mW 
Energy density 
320 J/cm2 
Dose 9 J 
Diameter tip 
600 μm 
Application 
time: 90s/site 
Not analysed Not analysed Test: 
PD decrease from 
5.11±0.56 to 2.83±0.47 
(n.s.) 
CAL change from 
5.49±0.76 to 3.41 ± 0.84 
(n.s.) 
BOP: from 61.58± 15.64 to 
36.73±19.72 (n.s.) 
Control: 
PD decrease from 
5.15±0.46 to 2.83±0.40 
CAL change from 
5.53±0.54 to 3.39 ± 0.51 
BOP: from 62.23± 16.91 to 
38.49±20.52 
 
 
Berakdar et al. 
(2012)24 
Germany 
Split-mouth, RCT 
ChP N=22 
10/12 
59.3±11.7 
no smokers 
6 
months 
Test: 
SRP+PDT 
Control: 
SRP 
Methylene blue 
0.005% 
Diode laser 
(Periowave) 
Wavelength 
670 nm 
Max. power 
150 mW 
Application 
time 60s 
Not analysed Not analysed Test: 
PD: 2.9±0.8* 
CAL: n.s. changes n.r. 
BOP: from 100% to 13.6% 
n.s. 
Control: 
PD: 2.4±0.8 
BOP: from 100% to 22.7% 
CAL gain: n.s.  
Betsy et al. 
(2014)25 
India 
Parallel, RCT 
ChP N=88 
51/39 
39.6±8.7 
6 
months 
Test: 
SRP+PDT 
Control: 
SRP 
Phenothiazine 
chloride 
trihydrate 
(freshly 
prepared, 
Sigma-Aldrich, 
USA) 
Diode laser (CNI 
Opto-electronics 
Tech., China) 
Wavelength 
655 nm, output 
power 1W 
Power density 
60 mW/cm2 
Diameter tip 
0.5 mm 
Application 
time 60s/site 
  
Not analysed Not analysed Test: 
PD: from 5.7 (5.0-6.0,1.0) 
to 3.0 (2.0-6.0, 1.0)* 
CAL: from 6.5 (5.0-8.0, 1.4) 
to 4.0 (2.6-7.0, 2.0)* 
BOP:  data n.r. 
Control: 
PD: from 5.5 (4.2-6.0, 1.0) 
to 4.0 (2.0-6.0, 1.0) 
CAL: from 6.0 (4.2-8.0, 1.7) 
to 4.5 (2.0-7.0, 2.0) 
BOP: data n.r. 
Braun et al. 
(2008)26 
ChP N=20 
11/9 
3 
months 
Test: SRP 
+PDT 
Phenothiazine 
chloride 
Wavelength 
660 nm 
Not analysed Not analysed 
 
Test: 
Median (inter-quartile 
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Germany 
Split-mouth 
46.6±6.1 
no smokers 
Control: SRP (HELBO 
Photodynamic 
Sys., Austria) 
Power output 
100 mW 
Application 
time 10s/site 
range, Max, Min) 
PD: 3.6 (0.6, 5.3, 3.2)* 
CAL: 7.04 (1.63, 9.11, 
5.33)* 
BOP: 19 (11, 64, 2)* 
Control: 
Median (inter-quartile 
range, Max, Min) 
PD: 3.7 (0.6, 6.0, 3.4) 
CAL: 7.25 (2.02, 10,09, 
5.61) 
BOP: 24 (21, 61, 2) 
Christodoulides et 
al. (2008)31 
Parallel, RCT 
ChP N=24 
13/11 
45±8.11 
3 smokers 
6 
months 
Test: SRP + 
PDT 
Control: SRP 
Phenothiazine 
chloride 
(HELBO Blue 
Photosensiti-
zer) 
Diode laser 
(HELBO 
TheraLite Laser) 
Wavelength 
670 nm 
Output power 
75 mW 
Application 
time 
60 s/tooth 
No significant 
differences 
between the 
groups for Aa, Pg, 
Tf, Td, Pi, Pm, Fn, 
Cr, En, Ec, Cs 
Not analysed Test: 
PD: 0.9±0.3 (n.s.) 
CAL: 0.7±0.3 (n.s.) 
BOP: from 54±16% to 
10±5%* 
Control: 
PD: 0.7±0.7 
CAL: 0.5±0.5 
BOP: from 59±21% to 
20±4% 
Dilsiz et al. 
(2013)27 
Turkey 
Split-mouth, RCT 
ChP N=24 
14/10 
40.7±7.3 
no smokers 
6 
months 
Test1: PDT 
+ SRP 
Test2: KTPL 
+ SRP 
Control: SRP 
Methylene blue 
1% 
Diode Laser 
(Doctor Smile 
diode, Lambda 
Scientifica 
Vincenza , Italy) 
Wavelength 
808 nm 
Output power 
100 mW 
Application 
time 
60 s/site 
Dose 6J 
Fibre tip 
diameter 300 
μm 
Not analysed Not analysed 
 
Test 1: 
PD: 1.54±0.59* 
CAL: 1.54±1.10* 
BOP: from 88±0.34 to 
38±0.49 (n.s.) 
Test 2: 
PD: 2.08±1.02* 
CAL: 2.42±1.14* 
BOP: from 96±0.20 to 
42±0.50 (n.s.) 
Control: 
PD: 1.42±0.88 
CAL: 1.50±0.88 
BOP: from 92±0.28 to 
46±0.51 
Ge et al. (2011)32 
China 
Parallel, RCT 
ChP N=58 
28/30 
43±10 
9 smokers 
12 
weeks 
Test 1: SRP 
+ PDT 
(once) 
Test 2: SRP 
+ PDT 
(twice) 
Methylene blue 
0.01% 
Diode Laser 
(Periowave) 
Wavelength 
670 nm 
Output power 
140 mW 
Energy density 
21 J/cm2 
Not analysed Not analysed 
 
No significant difference for 
PD reduction and CAL 
gain. 
Significant higher BOP 
reduction in both test 
groups compared to the 
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Control: SRP Application 
time 
60 s/site 
Dose 6 J 
control group. 
Luchesi et al. 
(2013)33 
Brazil 
Parallel, RCT 
ChP 
Furcation 
defects 
N=37 
no smokers 
6 
months 
Test: 
SRP+PDT 
Control: 
SRP+non 
activated 
laser 
Methylene Blue 
Diode laser 
(Thera Lase 
DMC, Sao 
Paulo, Brazil) 
Wavelength 
660 nm, power 
output 60 mW 
Energy dose 
129 J/ cm2 
Fibre optics 
diameter 600 
μm 
Application 
time 60s/site 
Significant 
decrease in P.g. 
and T.f. in PDT 
group, however 
no significant 
differences 
between the 
groups. 
Significant 
reduction at 3 
months of GM-
CSF, IFN- γ, 
IL-6, and IL-8 
in favour to 
PDT. At 6 m, 
also significant 
reduction of IL-
1β in PDT 
group. 
No significant differences 
between the groups. 
Test: 
PD: 1.59±1.11 (n.s.) 
CAL: 0.78±1.54 (n.s.) 
BOP: from 100% to 37.50% 
(n.s.) 
Control: 
PD: 1.50±1.73 
CAL: 1.00±1.69 
BOP: from 100% to 55% 
Lui et al. 
(2011)34 
China 
Split-mouth, RCT 
ChP N=24 
14/10 
50 
no smokers 
3 
months 
Test: 
SRP+PDT 
Control: 
SRP 
Methylene blue 
Diode laser 
(Ezlase, 
BIOLASE 
Techn., USA) 
Wavelength 
940 nm  
Energy 1 W 
Application tie 
30 s/tooth 
Energy density 
4 J/cm2 
Fibre tip 
diameter 300 
μm 
Not analysed Significant 
reduction of IL-
1β at 1 wk in 
favour to PDT. 
Significant 
reduction of 
GCF at 1wk 
and 1 m in 
favour to PDT. 
Changes from baseline to 3 
m: 
Test: 
PD: from 4.7±0.8 to 3.1±0.5 
(n.s.) 
REC: from 0.8±1.2 to 
1.8±1.2 (n.s.) 
BOP from 94±06 to 39±14 
(n.s.) 
Control: 
PD from 4.5±0.7 to 3.2 ± 
0.3 
REC from 1.0±1.1 
to1.8±1.3 
BOP from 92±10 to 43±12 
Mettraux & Hüsler 
(2011)35 
Switzerland 
Split-mouth, RCT 
 
ChP N=19 6 
months 
Test: 
SRP+PDT 
Control: 
SRP 
Methylene Blue 
Softlaser 
(Lasotronic 
MED-701, Orcos 
Medical, 
Switzerland) 
Wavelength 
670nm, 
Energy output 
330 mW 
Energy density 
31 J/ cm2 
Application: 
transgingival 
1min/site 
Fiber tip 
diameter 8mm 
 
Significant 
reduction of the 
total bacterial load 
in favour to PDT. 
Significant 
reduction of T.d. 
in both groups. 
Not analysed Test: 
PD: 2.1±1.4 (n.s.) 
CAL: 1.5±1.3 (n.s.) 
Control: 
PD: 1.5±1.6 
CAL: 0.9±1.7 
Polansky et al. ChP N=58 3 Test: SRP + Phenothiazine Wavelength No significant Not analysed Test: 
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(2009)36 
Austria 
Parallel, RCT 
36/22 
48.7 (25-67) 
7 smokers 
months PDT 
Control: SRP 
(ultrasound) 
chloride 
(HELBO Blue 
Photosensitizer) 
Diode laser 
(HELBO 
Minilaser 2075 
F, Grieskirchen, 
Austria) 
680 nm 
Output power 
75 mW 
Application 
time 
60 s/site 
difference for the 
reduction of P.g. 
between the 
groups; significant 
reduction of P.g. 
at 3 months 
compared to 
baseline in both 
groups. 
PD: from 5.79±1 to 
4.55±1.14 (n.s.) 
CAL: from 6.60±1.37 to 
5.25±1.41 (n.s.) 
BOP: from 100 to 47% 
(n.s.) 
Control: 
PD: from 5.53±1.15 to 
4.50±1.33 
CAL: from 6.59±1.23 to 
5.24±1.48 
BOP: from 100% to 59% 
 
Queiroz et al. 
(2014)39 
Brasil 
Split-mouth, RCT 
ChP N=20 
11/9 
46.05±6.38 
(35-55) 
smokers only 
3 
months 
Test: 
SRP+PDT 
Control: SRP 
Phenothiazine 
chloride 
(HELBO Blue 
Photosensitizer) 
Diode laser 
(HELBO 
Minilaser 2075 
F, Grieskirchen, 
Austria) 
Wavelength 
660 nm, 
Maximum 
power 60mW/ 
cm2 
Fiber tip 
diameter 0.6 
mm 
Application 
time 10 s/site 
at 6 sites/tooth 
40 subgingival 
bacteria were 
analysed: no 
significant 
differences 
between the 
groups or the 
timepoints 
Presented in 
Queiroz et al 
201529 
Presented in Queiroz et  
al. 201529 
Queiroz et al. 
(2015)29 
Brasil 
Split-mouth, RCT 
ChP N=20 
11/9 
46.05±6.38 
(35-55) 
smokers only 
3 
months 
Test: 
SRP+PDT 
Control: SRP 
Phenothiazine 
chloride 
(HELBO Blue 
Photosensitizer) 
Diode laser 
(HELBO 
Minilaser 2075 
F, Grieskirchen, 
Austria) 
Wavelength 
660 nm, 
Maximum 
power 60mW/ 
cm2 
Fiber tip 
diameter 0.6 
mm 
Application 
time 10 s/site 
at 6 sites/tooth 
Presented in 
Queiroz et al. 
201439 
Significant 
reduction of IL-
1β at 1 wk in 
favour to PDT. 
Significant 
reduction of 
MMP 8 at 12 
wk in favour to 
PDT. 
 
  
No significant differences 
between the groups. 
Test: 
PD: 1.58±1.28 (n.s.) 
CAL: 1.41±1.58 (n.s.) 
Control: 
PD: 1.81±0.52 
CAL: 1.60±0.92 
Sigusch et al. 
(2010)28 
Parallel, RCT 
ChP N=24 
17/7 
32-58 
no smokers 
12 
weeks 
Test: SRP + 
PDT 
Control: SRP 
Phenothiazine 
chloride 
(HELBO Blue 
Photosensitizer) 
Diode laser 
(HELBO 
Thera Lite 
Laser) 
Wavelength 
660 nm 
Power density 
60 mW/cm2 
Application 
time 
10 s/site 
Significant 
reduction of F.n. 
in the test group 
compared to the 
control group. 
Not analysed Test: 
Significant difference at 
12 weeks between the 
groups regarding mean 
PD* (data n.r.) 
Median, interquartile 
range:  
CAL: 2.45, 0.68* 
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REC: 0.20, 0.18 
BOP: from 66 to 18 %* 
Control: 
Median, interquartile 
range:  
PD: data n.r. 
CAL: 0.20, 0.18 
REC: 0.20, 0.10 
BOP: from 68 to 72% 
Srikanth et al. 
(2015)37 
India 
Split-mouth, RCT 
ChP N=39 
(30-55) 
nonsmokers 
6 
months 
Test1: 
SRP+PDT 
Test 2: SRP 
+laser 
without 
photosensitiz
er 
Control: 
SRP 
Indocyanine 
green 
(Aurogreen 
Aurolabs) 
Diode laser (firm 
not specified) 
Wavelength 
810 nm 
Power output 
0.7 W 
Application 
time 5 s/site 
Significant 
decrease of the % 
of viable bacteria 
in favour to PDT 
Not analysed Test 1: 
PD: from 5.81±0.89 to 
3.07±0.68(n.s.) 
CAL: from 5.00±0.80 to 
2.53±0.58 (n.s.) 
BOP: n.r. 
Test 2: 
PD: 5.34±0.34 to 3.15 v 
0.43 (n.s.) 
CAL: from 4.57±0.57 to 
2.96±0.44* 
BOP: n.r. 
Control: 
PD: from 5.07±0.27 to 
3.01±0.21  
CAL: from 4.50±0.50 to 
3.10±0.01 
BOP: n.r. 
Theodoro et al. 
(2012)38 
Brazil 
Split-mouth, RCT 
ChP N=33 
21/12 
43.12±8.2 
nonsmokers 
6 
months 
Test1: SRP 
+ PDT  
Test2: SRP 
+ Placebo 
PDT 
Control: SRP 
Phenothiazine 
100 μg/ml 
(Sigma 
Chemical, St. 
Louis, USA) 
Diode Laser 
(BioWave) 
Wavelength 
660 nm 
Power output 
30 mW 
Power 
intensity 0.4 
W/cm2 
Energy density 
64.28 J /cm2 
Application 
time 
150 s/site 
Spot size 0.07 
cm2 
A.a., P.g., P.i., 
T.f., P.n. 
Significant 
differences in all 
investigated 
periodontopathog
ens in favour to 
SRP +  PDT. 
Not analysed Test 1: 
PD: from 5.75± 1.44 to 
3.42±1.15 (n.s.) 
CAL: from 6.52±2.11 to 
4.96±2.07 (n.s.) 
BOP: from 93.9% to 45.5% 
(n.s.) 
Test 2: 
PD: from 5.88±1.26 to 
2.48±1.0 (n.s.) 
CAL: from 6.37±1.56 to 
4.38±1.82 (n.s.) 
BOP: from 97% to 39.4% 
(n.s.) 
Control: 
PD: from 5.81±1.0 to 
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3.1±0.83 
CAL: from 6.23±1.25 to 
4.25±1.73 
BOP: from 97% to 27.3% 
 
n.s.: not significant; n.r.: not reported; REC: recession; IL: Interleukin; MMP: Matrixmetalloproteinases; T.f.: Tannerella forsythia, P.g.: Porphyromonas gingivalis; A.a.: 
Aggregatibacter actinomycetemcomitans; T.d.: Treponema denticola; F.n.: Fusobacterium nucleatum; P.i.: Prevotella intermedia; C.r.: Campylobacter rectus; E.c.: Eikenella 
corrodens; P.m.: Parvimonas micra; E.n.: Eubacterium nodatum; C.s.:Capnocytophaga Spp. 
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Table 2. Photodynamic therapy as initial periodontal therapy in patients with AgP (data of 3 studies reported in 4 publications) 
 
Study  
Author 
Year 
Country 
Type 
Diagnosis Patients 
Female/male 
Age 
Smokers 
Study 
duration 
Treatment Photosensitiz
er 
Laser 
Laser 
parameters 
Microbiology 
 
Immunology PD reduction (mm) 
CAL gain (mm) 
BOP reduction (%) 
Chitsazi et al. 
(2014)40 
Iran 
Split-mouth, RCT 
 
AgP N=24 
15/9 
29 
3 
months 
Test: 
SRP+PDT 
Control: 
SRP 
Toluidine Blue 
photosensitize 
(Sigma 
chemical Co., 
St. Louis, Mo) 
Diode Laser 
(HANDY 
Laser, USA) 
Wavelength 
670-690 nm 
Power 75 mW 
Application 
time 2 min/site 
No significant 
differences for the 
levels of A.a. were 
observed between 
the groups 
Not analysed Test: 
PD change: from 5.79±1.06 
to 4.29±0.95 (n.s.) 
CAL change: from 
6.58±0.83 to 5.29±1.26 
(n.s.) 
BOP change: from 91.7% 
to 75% (n.s.) 
Control: 
PD change: from 5.45±0.77 
to 4.54±0.88 
CAL change: from 
6.25±1.07 to 5.50±1.18 
BOP change: from 100% to 
37.5% 
Moreira et al. 
(2015)41 
Brazil 
Split-mouth, RCT 
AgP N=20 
30.6±4.25 
18/2 
non smokers 
3 
months 
Test: 
SRP+PDT 
Control: SRP 
Phenothiazine 
chloride 
(HELBO Blue 
Photodynamic 
systems, 
Grieskirchen, 
Austria) 
Diode laser 
(HELBO 
Minilaser 2075 
F, 
Grieskirchen, 
Austria) 
Wavelength 
670 nm 
Maximum 
power 75 mW 
Fiber tip 
diameter 0.6  
Mm 
Energy density 
2.49 J/ cm2 
Application 
time 10s/site 
Significant less 
periodontal 
pathogens of the 
red and orange 
complex in the 
test group. 
Significant less 
IL-1β/IL-10 
ratio in the test 
group. 
No differences between 
the groups for moderate 
pockets.  
In deep pockets 
(PD≥7mm), significant 
PD decrease and CAL 
gain in favour to PDT: 
Test (deep pockets):  
PD from 7.73±0.87 to 
3.77±0.97 * 
CAL: from 7.84±0.89 to 
5.07±0.64* 
BOP: from 144±60 to 
22±13.75 (n.s.) 
Control (deep pockets): 
PD: from 7.68±0.92 to 
5.12±0.8 
CAL: from 7.75±1.21 to 
6.00±1.04. 
BOP: from 154±64.16 to 
36±15 
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Novaes et al. 
(2012)43 
Brazil 
Split-mouth, RCT 
AgP N=10 
8/2 
31 (18-35) 
nonsmokers 
3 
months 
Test: PDT 
Control: SRP 
Phenothiazine 
chloride 
(Helbo blue 
photosensitize
r) 
Minilaser 
(HELBO, 
Grieskirchen, 
Austria) 
Wavelength 
660 nm, 
Power 0.06W/ 
cm2, 
fluency 212.23 
J/ cm2 
Appliction time 
10s/site 
40 subgingival 
species were 
determined. 
PDT reduced 
significantly A.a. 
compared to SRP; 
SRP is more 
efficient for the 
red complex than 
PDT. In PDT a 
recolonisation of 
T.f. and P.g. was 
observed. 
Not analysed Published in Oliveira et 
al. 200742  
Oliveira et al.  
(2007)42 
Brazil 
Split-mouth, RCT 
AgP N=10 
8/2 
31 (18-35) 
nonsmokers 
3 
months 
Test: PDT 
Control: SRP 
Phenothiazine 
chloride 
(Helbo blue 
photosensitize
r) 
Minilaser 
(HELBO, 
Grieskirchen, 
Austria) 
Wavelength 
660 nm, 
Power 60 mW/ 
cm2, 
fluency 212.23 
J/ cm2 
Appliction time 
10s/site 
Published in 
Novaes et al. 
2011 
Not analysed Test: 
PD: from 4.92±1.61 to 
3.49±0.98 (n.s.) 
CAL: from 9.93±2.10 to 
8.74±2.12 (n.s.) 
BOP: from 57% to 19% 
(n.s.) 
Control: 
PD: from 4.92±1.14 to 
3.98±1.76  
CAL: from 10.53±2.30 to 
9.01±3.05 
BOP: from 60% to 21% 
          
n.s.: not significant; n.r.: not reported; REC: recession; IL: Interleukin; T.f.: Tannerella forsythia, P.g.: Porphyromonas gingivalis; A.a.: Aggregatibacter actinomycetemcomitans; 
T.d.: Treponema denticola; F.n.: Fusobacterium nucleatum; P.i.: Prevotella intermedia; C.r.: Campylobacter rectus; E.c.: Eikenella corrodens; P.m.: Parvimonas micra; E.n.: 
Eubacterium nodatum; C.s.:Capnocytophaga Spp. 
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Table 3. Photodynamic therapy in Supportive Periodontal Therapy (data of 8 studies reported in 9 publications) 
 
Study  
Author 
Year 
Country 
Type 
Diagnosis Patients 
Female/male 
Age 
Smokers 
Study 
duration 
Treatment Photosensitizer 
Laser 
Laser 
parameters 
Microbiology 
 
Immunology PD reduction (mm) 
CAL gain (mm) 
BOP reduction (%) 
Campos et al. 
(2013)44 
Brazil 
Split-mouth, RCT 
ChP n=13 
8/5 
48.15±7.53 
no smokers 
3 months Test: 
SRP+PDT 
Control: 
SRP 
Methylene 
blue  
10 mg/ml 
Diode laser 
(Thera Lase-
DMC, Brazil) 
Wavelength 
660 nm 
Power output 
60 mW 
Energy density 
129 J/cm2 
Application 
time 60s/site 
Not analysed Not analysed Test: 
PD: 2.17±0.91* 
CAL: 1.43±1.61* 
BOP: 77.78* 
Control: 
PD: 1.14±1.53 
CAL: 0.51±0.76* 
BOP: 40% 
Cappuyns et al. 
(2012)49 
Switzerland 
Split-mouth, RCT 
ChP N=29 
8/21 
52 (36-74) 
12 smokers 
6 months Test 1: 
SRP+PDT 
Test 2: 
SRP+Diode 
Soft Laser 
(DSL) 
Control: SRP 
Phenothiazine 
chloride 
(HELBO Blue 
Photosensitize
r) 
Diode Laser 
(Helbo 
Photodynamic 
Sys) 
Wavelength 
660 nm 
Power output 
40 mW 
Application 
time 60s/site 
A.a, P.g., T.f., 
T.d., total bacterial 
load 
No significant 
difference in the 
investigated 
microbiological 
parameters. 
However, P.g., 
T.f., and T.d. were 
suppressed 
stronger in the 
PDT group. 
Not analysed Test 1: 
PD: from 5.6±1.2 to 
3.8±1.2 (n.s.) 
REC: from 0.8±1.3 to 
1.0±1.3 (n.s.) 
BOP:  at 6m 15% (n.s.) 
Test 2: 
PD: from 5.5±0.7 to 
3.9±1.0 (n.s.) 
REC: from 0.8±1.7 to 
1.3±1.8 (n.s.) 
BOP: at 6m18% (n.s.) 
Control: 
PD: from 5.5±1.0 to 
3.6±1.1 
REC: from 0.7±1.3 to 
1.0±1.3 
BOP: at 6m 12% 
Chondros et al. 
(2009)46 
Netherlands 
Parallel, RCT 
ChP N=24 
14/10 
Test: 50.6±9.2 
Control: 
48.3±7.9 
7 smokers 
6 months Test: 
SRP+PDT 
Control: SRP 
Phenothiazine 
chloride 
(HELBO Blue 
Photosensitize
r) Diode laser 
(HELBO 
minilaser 
2075F) 
Wavelength 
670 nm 
Output power 
75 mW/cm2 
Application 
time 60 s/tooth 
A.a., P.g., P.i., 
T.f., T.d., P.m., 
F.n., C.r., E.n., 
E.c., C.s. 
Significant 
reduction of T.d., 
E.c., C.s. was 
found in favour of 
SRP+PDT 
Not analysed Test: 
PD: 0.8±0.5 (n.s.) 
CAL: 0.7±0.7 (n.s.) 
BOP: from 15±12 to 
12±05* 
Control: 
PD: 0.9±0.8 
CAL: 0.5±0.6 
BOP: from 19±14 to 
18±08 
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Giannopoulou et 
al. (2012)52 
Switzerland 
Split-mouth, RCT 
ChP N=29 
8/21 
52 (36-74) 
12 smokers 
6 months Test 1: 
SRP+PDT 
Test 2: 
SRP+diode 
laser (DL) 
Control: SRP 
Phenothiazine 
chloride 
(HELBO Blue 
Photosensitize
r) 
Diode Laser 
(Helbo 
Photodynamic 
Sys, 
Grieskirchen, 
Austria) 
Wavelength 
660 nm 
Power output 
100 mW 
Application 
time 60s/site 
Analysed in 
Cappuyns et al. 
2012 
Levels of 13 
cytokines and 
9 acute-phase 
proteins were 
measured. 
No significant 
differences 
were observed 
between the 
groups at any 
time point. 
See Cappuyns et al. 
2012 
Kolbe et al. 
(2014)47 
Brazil 
Split-mouth, RCT 
ChP N=21 
12/10 
48.52 (32-75) 
non smokers 
6 months Test 1: PDT 
Test 
2:Photosensi
tizer 
Control: SRP 
Methylene 
blue (10 
mg/ml) 
Diode laser 
(Thera Lase, 
Brazil) 
Wavelength 
660 nm 
Power output 
60 mW 
Energy dose 
129 J/cm2 
Application 
time 60s/site 
Lower * levels of 
A.a. were 
detected in Test1 
and Control 
groups at 3 as 
compared to 6 
months. 
Lower * detection 
frequency of P.g. 
for Test 1 and 
Control groups. 
IL-4 increased 
*in Test 1. 
IL-10 was 
reduced *in 
Test 2. 
Test 1 showed 
significant 
reduction of IL-
6, IL-1β 
IFN-γ. 
Test 1: 
PD: 1.6±1.20 (n.s.) 
CAL: 0.95±1.38 (n.s.) 
BOP: from 100% to 
28.57% (n.s.) 
Test 2: 
PD: 1.29±1.22 (n.s.) 
CAL: 0.69±1.30 (n.s.) 
BOP: from 100% to 
61.90%* 
Control: 
PD: 1.88±0.97 
CAL: 1.21±0.96 
BOP: from 100% to 
28.57% 
Lulic et al. 
(2009)45 
Parallel 
RCT 
ChP N=10 
3/7 
54 (40-74) 
2 smokers 
12 months Test: SRP + 
PDT 
Control: 
SRP+ 
Placebo: 
PDT 
Phenothiazine 
chloride 
(HELBO Blue 
Photosensitize
r) 
Diode laser 
(HELBO 
Minilaser 2075 
F) 
Wavelength 
670 nm 
Output power 
density 75 
mW/cm2 
Application 
time 
60 s/site 
Not analysed Not analysed Test: 
PD: -0.27± 0.43* 
CAL: -0.09± 0.41* 
BOP decrease 97-77* 
Control: 
PD: -0.07±0.61 
CAL: -0.20±0.61 
BOP increase 84-87 
Müller Campanile 
et al. (2015)50 
Switzerland 
Split-mouth, RCT 
ChP N=27 
13/14 
62.8 (37-77) 
6 months Test1: SRP 
+ PDT 
(twice) 
Test2: SRP 
+ PDT 
(once) 
Control: 
SRP+ 
Methylene 
blue  
Diode laser 
(Periowave, 
Ondine 
Biomedical, 
Vancouver, 
Canada) 
Wavelength 
670 nm 
Power output 
280 mW 
Application 
time 
60 s/site 
 
No significant 
changes of the 
microorganisms 
from baseline to 3 
/ 6 months in any 
of the group. 
No significant 
differences 
between the 
groups for IL-
1β, IL-1ra, IL-
8, IL-17, b-
FGF, G-GSF, 
GM-CSF, IFN-
Test 1:  
PD: from 5.9± 0.9 to 
3.1±1.0 (n.s.) 
CAL: from 7± 1.6 to 
4.1±1.6 (n.s.) 
BOP: from 16 to 10 
sites (n.s.) 
Test 2: 
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inactivated 
laser 
γ, MIP-1β, 
VEGF, TNF-α. 
C-reactive 
protein was 
significantly 
lower in the 
Test1 group, 
compared to 
the others. 
PD: from 6.3± 1.3 to 
2.9±1.8 (n.s.) 
CAL: from 7.9± 2.2 to 
4.2±2.8 (n.s.) 
BOP: from 20 to 7 sites 
(n.s.) 
Control: 
PD: from 6.3± 1.5 to 
3.4±1.5 
CAL: from 7.6± 2 to 
4.6±2.2 
BOP: from 15 to 10 
sites 
Petelin et al. 
(2014)48 
Slovenia 
Parallel, RCT 
ChP N=27 
12/15 
nonsmokers 
12 months Test 1: 
ultrasonic 
scaling 
(US)+PDT 
Test 2: US 
Control: SRP 
Phenothiazine 
chloride 
(HELBO Blue 
Photosensitize
r) 
Diode laser 
(HELBO Tera 
Light) 
Wavelength 
660 nm 
Output power 
density 60 
mW/cm2 
Application 
time 
60 s/site 
Assessment of 
A.a., P.g., P.i., 
T.f., T.d. 
Significant 
reduction of T.d. + 
sites and of A.a., 
T.f., T.d levels in 
favour to PDT in 
medium pockets 
(4-6mm), and of 
T.d. in deep 
pockets (>6mm).  
Not analysed Test 1:  
PD from 3.4±0.2 to 2.9±0.2 
(n.s.) 
CAL from 4.2±0.3 to 
3.7±0.2 (n.s.) 
BOP from25% to 9 %* 
Test 2: 
PD from 3.6±0.2 to 3.0±0.2 
(n.s.) 
CAL from 4.3±0.3 to 
3.7±0.2 (n.s.) 
BOP from 23% to 12% 
(n.s.) 
Control: 
PD from 3.8±0.2 to 3.3±0.2 
CAL from 4.7±0.3 to 
4.0±0.2 
BOP from 17% to 9% 
Rühling et al.  
(2010)51 
Germany 
Parallel, RCT 
ChP N=60 
48±8 
nonsmokers 
3 months Test: PDT 
Control: 
Ultrasonic 
debridement 
5% tolonium 
chloride 
(Asklepion 
Meditec, Fife, 
UK) 
Diode laser 
(SaveDent 
Dental Laser 
Sydstem, 
Asclepion 
Meditec. Ltd., 
Fife, UK) 
Wavelength 
635 nm 
Energy dose 
100 mW 
Application tie 
60 s/site 
Assessment of 
Microbial counts 
were reduced 
after treatment but 
returned to 
baseline values 
after 3 months. 
Not analysed No significant differences 
between the groups: 
Test: 
PD: from 3.5±0.4 to 3.3±0.5 
(n.s.) 
CAL: from 11.4±1.7 to 
11.4±1.6(n.s.) 
BOP: from 5.4±4.6 to 
3.3±4.3 (n.s.) 
Control: 
PD: from 3.3±0.5 to 3.1±0.4 
CAL: from 10.6±1.3 to 
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10.7±1.2 
BOP: from 4.7±4.8 to 
5.7±8.7 
          
  
n.s.: not significant; n.r.: not reported; REC: recession; IL: Interleukin; b-FGF: basic fibroblast growth factor; G-CSF: granulocyte colony stimulating factor; IFN-γ: interferon γ; MIP-
1β: macrophage inflammatory protein 1β; GM-CSF: granulocyte macrophage colony stimulating factor; TNF-α: tumor necrosis factor α; CRP: C-reactive protein; VEGF: vascular 
endothelial growth factor; T.f.: Tannerella forsythia, P.g.: Porphyromonas gingivalis; A.a.: Aggregatibacter actinomycetemcomitans; T.d.: Treponema denticola; F.n.: Fusobacterium 
nucleatum; P.i.: Prevotella intermedia; C.r.: Campylobacter rectus; E.c.: Eikenella corrodens; P.m.: Parvimonas micra; E.n.: Eubacterium nodatum; C.s.:Capnocytophaga Spp. 
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